Can 4DMedicals Breakthrough Tech Gain Momentum After Mayo Clinic Adoption?
Source: Kapitales Research
Highlights:
Mayo Clinic adopts CT:VQ™, marking a major milestone for 4DMedical’s global expansion
Six top U.S. medical centres onboarded within ~7 months of FDA clearance, signalling strong traction
Strategic win despite limited short-term revenue, with potential to accelerate broader adoption
4DMedical Limited (ASX: 4DX) has secured a significant institutional endorsement, with the Mayo Clinic deploying its CT:VQ™ technology for advanced lung imaging, strengthening the company’s foothold in the U.S. healthcare market.
Landmark Adoption Strengthens Market Position
The Mayo Clinic—widely regarded as the leading hospital in the United States—has begun using CT:VQ™ to analyse lung ventilation and perfusion. This move represents a key validation of 4DMedical’s technology, as the institution is known for influencing clinical practices and technology adoption globally. While the initial agreement is limited in financial impact, its strategic value is substantial. The deployment allows clinicians to integrate the technology into workflows and evaluate its use across a wide range of clinical scenarios.
Rapid Expansion Across Elite Institutions
The latest deployment marks 4DMedical’s sixth U.S. Academic Medical Center adoption, joining leading institutions such as Stanford, Cleveland Clinic, and the University of Chicago Medicine.
Notably, these milestones have been achieved within approximately seven months of FDA clearance, highlighting the rapid uptake of CT:VQ™ among top-tier healthcare providers. This pace of adoption reflects growing confidence in the technology’s clinical utility.
Technology Advantage Driving Adoption
CT:VQ™ offers several advantages over traditional imaging methods, including eliminating the need for radioactive materials or contrast agents and delivering enhanced imaging precision. It also integrates seamlessly with existing CT systems, making it easier for hospitals to adopt without major infrastructure changes. These features position the technology as a compelling alternative in lung diagnostics, particularly in pulmonary and cardiothoracic care.
Momentum Building for Commercial Growth
With a growing network of high-profile institutions and an expanding commercial pipeline, 4DMedical appears to be building strong momentum in the U.S. market. The Mayo Clinic deployment could act as a key reference point, potentially accelerating adoption across other healthcare systems.
As the company continues to scale its presence, the focus now shifts to converting these strategic wins into long-term commercial growth and broader industry adoption.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Can 4DMedicals Breakthrough Tech Gain Momentum After Mayo Clinic Adoption?
Highlights:
Mayo Clinic adopts CT:VQ™, marking a major milestone for 4DMedical’s global expansion
4DMedical Limited (ASX: 4DX) has secured a significant institutional endorsement, with the Mayo Clinic deploying its CT:VQ™ technology for advanced lung imaging, strengthening the company’s foothold in the U.S. healthcare market.
Landmark Adoption Strengthens Market Position
The Mayo Clinic—widely regarded as the leading hospital in the United States—has begun using CT:VQ™ to analyse lung ventilation and perfusion. This move represents a key validation of 4DMedical’s technology, as the institution is known for influencing clinical practices and technology adoption globally. While the initial agreement is limited in financial impact, its strategic value is substantial. The deployment allows clinicians to integrate the technology into workflows and evaluate its use across a wide range of clinical scenarios.
Rapid Expansion Across Elite Institutions
The latest deployment marks 4DMedical’s sixth U.S. Academic Medical Center adoption, joining leading institutions such as Stanford, Cleveland Clinic, and the University of Chicago Medicine.
Notably, these milestones have been achieved within approximately seven months of FDA clearance, highlighting the rapid uptake of CT:VQ™ among top-tier healthcare providers. This pace of adoption reflects growing confidence in the technology’s clinical utility.
Technology Advantage Driving Adoption
CT:VQ™ offers several advantages over traditional imaging methods, including eliminating the need for radioactive materials or contrast agents and delivering enhanced imaging precision. It also integrates seamlessly with existing CT systems, making it easier for hospitals to adopt without major infrastructure changes. These features position the technology as a compelling alternative in lung diagnostics, particularly in pulmonary and cardiothoracic care.
Momentum Building for Commercial Growth
With a growing network of high-profile institutions and an expanding commercial pipeline, 4DMedical appears to be building strong momentum in the U.S. market. The Mayo Clinic deployment could act as a key reference point, potentially accelerating adoption across other healthcare systems.
As the company continues to scale its presence, the focus now shifts to converting these strategic wins into long-term commercial growth and broader industry adoption.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au